CY1112663T1 - Εμβολιο dνα εναντι πολλαπλασιαζομενων ενδοθηλιακων κυτταρων και μεθοδοι χρησεως αυτου - Google Patents
Εμβολιο dνα εναντι πολλαπλασιαζομενων ενδοθηλιακων κυτταρων και μεθοδοι χρησεως αυτουInfo
- Publication number
- CY1112663T1 CY1112663T1 CY20111101264T CY111101264T CY1112663T1 CY 1112663 T1 CY1112663 T1 CY 1112663T1 CY 20111101264 T CY20111101264 T CY 20111101264T CY 111101264 T CY111101264 T CY 111101264T CY 1112663 T1 CY1112663 T1 CY 1112663T1
- Authority
- CY
- Cyprus
- Prior art keywords
- seq
- dna
- methods
- cells
- multiplicated
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 4
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 abstract 4
- 108010041986 DNA Vaccines Proteins 0.000 abstract 3
- 229940021995 DNA vaccine Drugs 0.000 abstract 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 3
- -1 (SEQ ID NO: 4) Proteins 0.000 abstract 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 abstract 1
- 241000283984 Rodentia Species 0.000 abstract 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 1
- 230000003527 anti-angiogenesis Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Ένα εμβόλιο DΝΑ αποτελεσματικό για την αναστολή του πολλαπλασιασμού των ενδοθηλιακών κυττάρων περιλαμβάνει ένα μόρφωμα DΝΑ που κωδικοποιεί λειτουργικά μία πρωτεΐνη υποδοχέα αγγειακού ενδοθηλιακού αυξητικού παράγοντα (VEGF). Η παρούσα εφεύρεση παρέχει εμβόλια DΝΑ που κωδικοποιούν τον υποδοχέα-2 του VEGF (ΚDR, ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 2), τον υποδοχέα-1 του VEGF (Flt-1, (ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 4), ή Flk-1 (το ομόλογο του ΚDR τρωκτικών, ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 6), τις αλληλουχίες DΝΑ ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 1, 3, και 5 αντιστοίχως, καθώς επίσης και μεθόδους χρήσεως ενός τέτοιου εμβολίου DΝΑ για την αναστολή του πολλαπλασιασμού των αγγειακών ενδοθηλιακών κυττάρων στο μικροπεριβάλλον του όγκου. Επιτυγχάνεται αντι-αγγειογένεση και επακόλουθη μείωση της αναπτύξεως και της διασποράς του όγκου.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/090,183 US7094410B2 (en) | 2002-03-02 | 2002-03-02 | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| EP03726007A EP1487482B1 (en) | 2002-03-02 | 2003-02-28 | Dna vaccine against proliferating endothelial cells and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112663T1 true CY1112663T1 (el) | 2016-02-10 |
Family
ID=27787599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111101264T CY1112663T1 (el) | 2002-03-02 | 2011-12-20 | Εμβολιο dνα εναντι πολλαπλασιαζομενων ενδοθηλιακων κυτταρων και μεθοδοι χρησεως αυτου |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7094410B2 (el) |
| EP (1) | EP1487482B1 (el) |
| JP (1) | JP4598401B2 (el) |
| KR (1) | KR100979898B1 (el) |
| CN (1) | CN1293917C (el) |
| AT (1) | ATE528015T1 (el) |
| AU (1) | AU2003228229B2 (el) |
| BR (1) | BRPI0308103B8 (el) |
| CA (1) | CA2477406C (el) |
| CY (1) | CY1112663T1 (el) |
| DK (1) | DK1487482T3 (el) |
| ES (1) | ES2371870T3 (el) |
| MX (1) | MXPA04008468A (el) |
| PL (1) | PL213364B1 (el) |
| PT (1) | PT1487482E (el) |
| RU (1) | RU2318019C2 (el) |
| SI (1) | SI1487482T1 (el) |
| WO (1) | WO2003073995A2 (el) |
| ZA (1) | ZA200406988B (el) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1595548A3 (en) * | 2001-03-07 | 2006-02-22 | Mannkind Corporation | Anti-neovasculature preparations for treating cancer |
| US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| KR100614220B1 (ko) | 2004-11-08 | 2006-08-21 | 고려대학교 산학협력단 | Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물 |
| CN101766818B (zh) * | 2008-12-30 | 2013-05-22 | 陕西北美基因股份有限公司 | 多糖金磁复合微粒载药体及其制备方法 |
| JP5539411B2 (ja) * | 2009-03-04 | 2014-07-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 血管新生因子を含む組成物およびその使用方法 |
| US9492523B2 (en) | 2011-12-09 | 2016-11-15 | The Board Of Regents For Oklahoma State University | Broadly protective Shigella vaccine based on type III secretion apparatus proteins |
| ES2650269T3 (es) * | 2011-12-22 | 2018-01-17 | Vaximm Ag | Método para producir cepas atenuadas de salmonela de alto rendimiento |
| CN104519908B (zh) | 2012-07-05 | 2020-10-30 | 万科斯蒙股份有限公司 | 用于胰腺癌患者的dna疫苗 |
| WO2014034735A1 (ja) | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Ｖｅｇｆ及び／又はアンギオポエチン－２の特異的エピトープを含むｄｎａワクチン |
| US10548962B2 (en) | 2012-10-22 | 2020-02-04 | The Board Of Regents For Oklahoma State University | Use of the salmonella SPP type III secretion proteins as a protective vaccination |
| US9950053B2 (en) | 2012-10-22 | 2018-04-24 | The Board Of Regents For Oklahoma State University | Use of the Salmonella SPP type III secretion proteins as a protective vaccination |
| US20180153976A1 (en) | 2015-06-18 | 2018-06-07 | Vaximm Ag | Novel cmv pp65 targeting dna vaccine for cancer immunotherapy |
| JP6947649B2 (ja) | 2015-06-18 | 2021-10-13 | バクシム アクチェンゲゼルシャフト | 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン |
| RU2759227C2 (ru) * | 2020-04-10 | 2021-11-11 | Генетик Диагностикс Энд Терапи 21 Лтд | ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US6228844B1 (en) * | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US5939400A (en) * | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| CA2310252A1 (en) * | 1998-03-06 | 1999-09-10 | Imclone Systems Incorporated | Active immunization against angiogenesis-associated antigens |
| WO2000014244A2 (en) * | 1998-09-04 | 2000-03-16 | Connaught Laboratories Limited | Treatment of cervical cancer |
| AU2001271976A1 (en) * | 2000-07-07 | 2002-01-21 | Corixa Corporation | Microspheres and adjuvants for dna vaccine delivery |
| US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
-
2002
- 2002-03-02 US US10/090,183 patent/US7094410B2/en not_active Expired - Lifetime
-
2003
- 2003-02-28 EP EP03726007A patent/EP1487482B1/en not_active Expired - Lifetime
- 2003-02-28 PL PL372314A patent/PL213364B1/pl unknown
- 2003-02-28 MX MXPA04008468A patent/MXPA04008468A/es active IP Right Grant
- 2003-02-28 KR KR1020047013668A patent/KR100979898B1/ko active IP Right Grant
- 2003-02-28 RU RU2004129332/13A patent/RU2318019C2/ru active
- 2003-02-28 SI SI200332080T patent/SI1487482T1/sl unknown
- 2003-02-28 PT PT03726007T patent/PT1487482E/pt unknown
- 2003-02-28 CA CA2477406A patent/CA2477406C/en not_active Expired - Lifetime
- 2003-02-28 BR BRPI0308103A patent/BRPI0308103B8/pt not_active IP Right Cessation
- 2003-02-28 CN CNB038099470A patent/CN1293917C/zh not_active Expired - Lifetime
- 2003-02-28 DK DK03726007.2T patent/DK1487482T3/da active
- 2003-02-28 WO PCT/US2003/006256 patent/WO2003073995A2/en active Application Filing
- 2003-02-28 JP JP2003572517A patent/JP4598401B2/ja not_active Expired - Lifetime
- 2003-02-28 AU AU2003228229A patent/AU2003228229B2/en not_active Expired
- 2003-02-28 ES ES03726007T patent/ES2371870T3/es not_active Expired - Lifetime
- 2003-02-28 AT AT03726007T patent/ATE528015T1/de active
-
2004
- 2004-09-01 ZA ZA2004/06988A patent/ZA200406988B/en unknown
-
2006
- 2006-08-21 US US11/507,298 patent/US8048428B2/en active Active
-
2011
- 2011-10-25 US US13/280,855 patent/US8241637B2/en not_active Expired - Lifetime
- 2011-12-20 CY CY20111101264T patent/CY1112663T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112663T1 (el) | Εμβολιο dνα εναντι πολλαπλασιαζομενων ενδοθηλιακων κυτταρων και μεθοδοι χρησεως αυτου | |
| CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| US10550197B2 (en) | CAR-expressing NK-92 cells as cell therapeutic agents | |
| CY1109463T1 (el) | Πεπτιδια kdr και εμβολια που τα περιλαμβανουν | |
| Nimanong et al. | CD40 signaling drives potent cellular immune responses in heterologous cancer vaccinations | |
| CY1105439T1 (el) | Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση | |
| DE60130797D1 (de) | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose | |
| CY1108474T1 (el) | Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων | |
| ATE296351T1 (de) | Cck-2, eine rezeptor tyrosin kinase | |
| Shin et al. | Lentivirus delivery by adsorption to tissue engineering scaffolds | |
| Matejuk et al. | Vaccines targeting the neovasculature of tumors | |
| Cavallo et al. | Xenogene vaccination in the therapy of cancer | |
| ATE237928T1 (de) | Herbizide mittel von nachauflauf-herbiziden zur bodenapplikation | |
| Shukla et al. | An Engineered Prussian Blue Nanoparticles‐Based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH‐MYCN Neuroblastoma Model | |
| DK0939809T3 (da) | TIE-2 receptor-ligand (TIE ligand-4) og dens anvendelse | |
| CA2466530A1 (en) | Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell | |
| ATE285250T1 (de) | Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien | |
| ES2286893T3 (es) | Proteina de union a guanilato (gbp-1) como inhibidor de la proliferacion celular. | |
| Ibanez et al. | GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells | |
| Dutoit et al. | Immunotherapy of brain tumors | |
| Bella et al. | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis | |
| Huang et al. | Development of the LYVE‐1 gene with an acidic‐amino‐acid‐rich (AAAR) domain in evolution is associated with acquisition of lymph nodes and efficient adaptive immunity | |
| DE60032293D1 (de) | Lebende attenuierte bakterien zur verwendung als impfstoff | |
| DK1444261T3 (da) | Immunogene ALK (anaplastisk lymfomakinase) peptider | |
| Hart | Biology of cancer |